Stocktoria
Xencor Inc XNCR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-12-03
Xencor Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $125.6M | $110.5M | $174.6M | $164.6M | $275.1M |
| R&D expense | $239.4M | $227.7M | $253.6M | $199.6M | $192.5M |
| Operating income | -$177.5M | -$178.4M | -$132.4M | -$82.5M | $43.8M |
| Income tax | $2.5M | $1.6M | $13.7M | $673,000 | $0 |
| Net income | -$91.9M | -$232.6M | -$133.1M | -$55.2M | $82.6M |
| EPS (diluted) | $-1.24 | $-3.58 | $-2.20 | $-0.93 | $1.37 |
| Operating cash flow | -$135.1M | -$202.2M | -$77.9M | $24.5M | -$16.9M |
| Free cash flow | -$138.3M | -$208.3M | -$96.4M | -$14.0M | -$30.2M |
| Cash & equivalents | $54.1M | $40.9M | $53.8M | $53.9M | $143.5M |
| Total assets | $875.5M | $951.9M | $965.1M | $846.3M | $838.2M |
| Total liabilities | $239.9M | $277.9M | $303.0M | $118.8M | $104.7M |
| Shareholders' equity | $635.6M | $677.6M | $662.1M | $727.5M | $733.5M |
Source: SEC EDGAR filings · CIK 0001326732 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.